NCT07079007

Brief Summary

Small Intestine Contrast Ultrasonography (SICUS) is an ultrasound-based method that explores bowel loops, and is able to identify wall thickness, intestinal motility, bowel wall vascularity and complications such as stenosis or dilatation. Previous studies have utilised oral ingestion of an oral contrast solution (usually PEG dissolved in a volume of water ranging from 250 to 1000mL), in order to increase the sensitivity of ultrasound, especially in stricture detection. Parameters that have been improved include lumen distension to better delineate bowel wall layers, and improved peristalsis. Diffusion of this technique has been limited, in part due to PEG-based agents being costly, time consuming and are not tolerated well in some individuals. Utilisation of water as oral contrast may improve patient tolerability and therefore increase uptake of water ingested intestinal contrast ultrasound (WICUS) as a technique in routine clinical practice. The investigators aim to study the tolerability and the improvement of image quality utilising water as an oral contrast for intestinal ultrasonography.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
55

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 30, 2025

Completed
1 day until next milestone

Study Start

First participant enrolled

July 1, 2025

Completed
21 days until next milestone

First Posted

Study publicly available on registry

July 22, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2026

Completed
Last Updated

July 22, 2025

Status Verified

June 1, 2025

Enrollment Period

4 months

First QC Date

June 30, 2025

Last Update Submit

July 18, 2025

Conditions

Keywords

small bowel contrast ultrasound

Outcome Measures

Primary Outcomes (1)

  • Improvement of luminal distension of the terminal ileum

    Improvement of luminal distension of the terminal ileum, defined as increase of 20% over baseline luminal diameter at the terminal ileum if no disease, taking the average as measured at 1cm intervals over 3cm of the TI in longitudinal view. If diseased segment is present, then measurements would be done at 1cm intervals over 3cm proximal to the diseased segments.

    At the post-water ingestion scan 20-30 minutes after ingestion

Secondary Outcomes (1)

  • Is image quality and visualisation of the terminal/distal ileum improved post water ingestion during intestinal ultrasound compared to baseline as assessed by blinded sonographers

    At the time of post-water ingestion scan 20-30 minutes after ingestion

Other Outcomes (9)

  • Grade of peristalsis

    At the time of post-water ingestion scan 20-30 mins after ingestion

  • Identification of suspected stricture

    At the post-water ingestion scan 20-30 minutes after ingestion

  • Measurement of bowel wall thickness

    At the post-water ingestion scan 20-30 minutes after ingestion

  • +6 more other outcomes

Study Arms (1)

IUS oral contrast

All patients already referred and scheduled to undertake an IUS in the single-centre IUS clinic would undergo a baseline procedure. Patients that meet the inclusion and exclusion criteria would be asked to ingest 1000ml water as part of standard of care. Inclusion Criteria All consecutive patients at baseline scan with: Confirmed or suspected Crohn's disease with small bowel involvement Increased bowel wall thickness (\>3mm) of the terminal ileum Suboptimal luminal distension of the terminal ileum 3cm proximal to ICV and 1cm proximal to diseased segment (defined as \<8mm) All patients with an ileo-colic anastomosis Exclusion Criteria Presence of an ostomy Adequate distension at baseline scan Patients with ileo-rectal anastomosis or IPAA

Other: Water

Interventions

WaterOTHER

Patients that meet the inclusion and exclusion criteria would be asked to ingest 1000ml water as part of standard of care.

IUS oral contrast

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients already referred and scheduled to undertake an IUS in the single-centre Austin Health IUS clinic would undergo a baseline procedure. Patients that meet the inclusion and exclusion criteria would be asked to ingest 1000ml water as part of standard of care.

You may qualify if:

  • All consecutive patients at baseline scan with:
  • Confirmed or suspected Crohn's disease with small bowel involvement
  • Increased bowel wall thickness (\>3mm) of the terminal ileum
  • Suboptimal luminal distension of the terminal ileum 3cm proximal to ICV and 1cm proximal to diseased segment (defined as \<8mm)
  • All patients with an ileo-colic anastomosis

You may not qualify if:

  • Presence of an ostomy
  • Adequate distension at baseline scan
  • Patients with ileo-rectal anastomosis or IPAA

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Austin Health

Heidelberg, Victoria, 3084, Australia

Location

MeSH Terms

Conditions

Crohn Disease

Interventions

Water

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

HydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen Compounds

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator: Julien Schulberg, MBBS, PhD , Austin Health, Melbourne

Study Record Dates

First Submitted

June 30, 2025

First Posted

July 22, 2025

Study Start

July 1, 2025

Primary Completion

November 1, 2025

Study Completion

February 1, 2026

Last Updated

July 22, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations